Citations (108)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
André J Scheen. (2019) An update on the safety of SGLT2 inhibitors. Expert Opinion on Drug Safety 18:4, pages 295-311.
Read now
Read now
Thomas Karagiannis, Eleni Bekiari & Apostolos Tsapas. (2017) Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. Core Evidence 12, pages 1-10.
Read now
Read now
Sayf A Yassin & Vanita R Aroda. (2017) Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. Drug Design, Development and Therapy 11, pages 923-937.
Read now
Read now
Tony B. Amos, Leslie Montejano, Paul Juneau & Susan C. Bolge. (2017) Healthcare costs of urinary tract infections and genital mycotic infections among patients with type 2 diabetes mellitus initiated on canagliflozin: a retrospective cohort study. Journal of Medical Economics 20:3, pages 303-313.
Read now
Read now
Rong Qiu, Dainius Balis, John Xie, Michael J. Davies, Mehul Desai & Gary Meininger. (2017) Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Current Medical Research and Opinion 33:3, pages 553-562.
Read now
Read now
Thomas C. Blevins & Azeez Farooki. (2017) Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Postgraduate Medicine 129:1, pages 159-168.
Read now
Read now
Koutaro Yokote, Yasuo Terauchi, Ichiro Nakamura & Haruko Sugamori. (2016) Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study. Expert Opinion on Pharmacotherapy 17:15, pages 1995-2003.
Read now
Read now
Curt J. Carlson & Marile L. Santamarina. (2016) Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Expert Opinion on Drug Safety 15:10, pages 1401-1412.
Read now
Read now
Richard F. Arakaki. (2016) Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Postgraduate Medicine 128:4, pages 409-417.
Read now
Read now
Stanley S. Schwartz & Intekhab Ahmed. (2016) Sodium–glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes. Current Medical Research and Opinion 32:5, pages 907-919.
Read now
Read now
Matthew R. Weir. (2016) The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. Postgraduate Medicine 128:3, pages 290-298.
Read now
Read now
Yasuo Terauchi, Koutaro Yokote, Ichiro Nakamura & Haruko Sugamori. (2016) Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study. Expert Opinion on Pharmacotherapy 17:4, pages 463-471.
Read now
Read now
André J. Scheen. (2015) SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opinion on Drug Safety 14:12, pages 1879-1904.
Read now
Read now
Jochen Seufert. (2015) SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes, Metabolic Syndrome and Obesity 8, pages 543-554.
Read now
Read now
Lawrence Blonde, Vincent Woo, Chantal Mathieu, Jacqueline Yee, Ujjwala Vijapurkar, William Canovatchel & Gary Meininger. (2015) Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Current Medical Research and Opinion 31:11, pages 1993-2000.
Read now
Read now
James R. Gavin$suffix/text()$suffix/text(), Melanie J. Davies, Michael Davies, Ujjwala Vijapurkar, Maria Alba & Gary Meininger. (2015) The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Current Medical Research and Opinion 31:9, pages 1693-1702.
Read now
Read now
Ambika Amblee. (2014) Patient profiling in diabetes and role of canagliflozin. Pharmacogenomics and Personalized Medicine 7, pages 367-377.
Read now
Read now
Rosemarie Lajara. (2014) The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 15:17, pages 2565-2585.
Read now
Read now
Vidhya Jahagirdar & Anthony H Barnett. (2014) Empagliflozin for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 15:16, pages 2429-2441.
Read now
Read now
Jaime A. Davidson & Louis Kuritzky. (2014) Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients with Type 2 Diabetes. Postgraduate Medicine 126:6, pages 33-48.
Read now
Read now
Stephen Brunton & Timothy S. Reid. (2014) Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, for the Management of Type 2 Diabetes. Hospital Practice 42:3, pages 96-108.
Read now
Read now
Articles from other publishers (87)
A. Pozzi, C. Cirelli, A. Merlo, F. Rea, C. Scangiuzzi, E. Tavano, A. Iorio, S. L. Kristensen, C. Wong, A. Iacovoni & G. Corrado. (2023) Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis. Heart Failure Reviews.
Crossref
Crossref
Golsa M. Yazdy, Caroline Mitchell, Jack D. Sobel & Susan Tuddenham. (2023) Recurrent Infectious Vaginitis. Medical Clinics of North America.
Crossref
Crossref
Jodi B. SegalRavi VaradhanRolf H.H. Groenwold, Nicholas C. HendersonXiaojuan Li, Kaori Nomura, Sigal Kaplan, Shirin Ardeshirrouhanifard, James Heyward, Fredrik Nyberg & Mehmet Burcu. (2023) Assessing Heterogeneity of Treatment Effect in Real-World Data. Annals of Internal Medicine 176:4, pages 536-544.
Crossref
Crossref
Joakim Huber, Michael Smeikal, Christoph H. Saely, Harald Stingl, Martin Clodi, Monika Lechleitner & Peter Fasching. (2023) Geriatrische Aspekte bei Diabetes mellitus (Update 2023)Geriatric aspects for the management of diabetes mellitus (Update 2023). Wiener klinische Wochenschrift 135:S1, pages 307-318.
Crossref
Crossref
Fadile Gaye Hösükoğlu, Fahriye Ekşi, Mehmet Erinmez & Mete Gürol Uğur. (2022) An Epidemiologic Analysis of Vulvovaginal Candidiasis and Antifungal Susceptibilities. Infectious Microbes and Diseases 4:3, pages 131-136.
Crossref
Crossref
Ryan Kurtz, Andrew Libby, Bryce A. Jones, Komuraiah Myakala, Xiaoxin Wang, Yichien Lee, Grace Knoer, Julia N. Lo Cascio, Michaela McCormack, Grace Nguyen, Elijah N. D. Choos, Olga Rodriguez, Avi Z. Rosenberg, Suman Ranjit, Christopher Albanese, Moshe Levi, Carolyn M. Ecelbarger & Blythe D. Shepard. (2022) Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice. International Journal of Molecular Sciences 23:10, pages 5675.
Crossref
Crossref
Věra Čertíková Chábová & Oskar Zakiyanov. (2022) Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes. International Journal of Molecular Sciences 23:5, pages 2812.
Crossref
Crossref
Buchun Jiang, Zhiwen Cheng, Fei Liu, Qiuyu Li, Haidong Fu & Jianhua Mao. (2021) Renoprotection with sodium‐glucose cotransporter‐2 inhibitors in children: Knowns and unknowns. Nephrology 27:2, pages 126-132.
Crossref
Crossref
Yao Wang, Xian Shao & Zewen Liu. (2022) Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in the elderly <i>versus</i> non-elderly patients with type 2 diabetes mellitus: a meta-analysis. Endocrine Journal 69:6, pages 669-679.
Crossref
Crossref
Wael A H Hegazy, Azza A H Rajab, Amr S Abu Lila & Hisham A Abbas. (2021) Anti-diabetics and antimicrobials: Harmony of mutual interplay. World Journal of Diabetes 12:11, pages 1832-1855.
Crossref
Crossref
Jenny E. Liles, Kendall Flanigan & Loretta S. Davis. (2021) Association of IL-17 Inhibitor and SGLT2 Inhibitor with Candida Pyelonephritis. The American Journal of Medicine 134:11, pages e561-e562.
Crossref
Crossref
SooJeong Ko, HyungMin Kim, Jiwon Shinn, Sun‐ju Byeon, Jeong‐Hee Choi & Hun‐Sung Kim. (2021) Estimation of sodium‐glucose cotransporter 2 inhibitor–related genital and urinary tract infections via electronic medical record–based common data model. Journal of Clinical Pharmacy and Therapeutics 46:4, pages 975-983.
Crossref
Crossref
Muhannad Alqudsi, Juan Carlos Q. Velez & Jose Navarrete. (2021) Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i). Current Opinion in Cardiology 36:4, pages 420-428.
Crossref
Crossref
Alex Farr, Isaak Effendy, Brigitte Frey Tirri, Herbert Hof, Peter Mayser, Ljubomir Petricevic, Markus Ruhnke, Martin Schaller, Axel P. A. Schaefer, Valentina Sustr, Birgit Willinger & Werner Mendling. (2021) Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k). Mycoses 64:6, pages 583-602.
Crossref
Crossref
Vishnu Vardhan Garla, Javed Butler & Lillian F. Lien. (2021) SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives. Current Cardiology Reports 23:6.
Crossref
Crossref
Alex Farr, Isaak Effendy, Brigitte Frey Tirri, Herbert Hof, Peter Mayser, Ljubomir Petricevic, Markus Ruhnke, Martin Schaller, Axel P. A. Schäfer, Birgit Willinger & Werner Mendling. (2021) Vulvovaginal Candidosis (Excluding Mucocutaneous Candidosis): Guideline of the German (DGGG), Austrian (OEGGG) and Swiss (SGGG) Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry Number 015/072, September 2020). Geburtshilfe und Frauenheilkunde 81:04, pages 398-421.
Crossref
Crossref
Muhammad Imtiaz Ahmad & Michael D. Shapiro. (2021) Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome. Current Atherosclerosis Reports 23:4.
Crossref
Crossref
Kazunori Utsunomiya, Ryusuke Koshida, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji & Kohei Kaku. (2020) Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real‐world clinical practice: Results of a 36‐month post‐marketing surveillance study (J‐STEP/LT). Journal of Diabetes Investigation 12:2, pages 184-199.
Crossref
Crossref
Wen-jie Li, Xing-qing Chen, Ling-ling Xu, Yuan-qing Li & Bi-hui Luo. (2020) SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovascular Diabetology 19:1.
Crossref
Crossref
Valentina Sustr, Philipp Foessleitner, Herbert Kiss & Alex Farr. (2020) Vulvovaginal Candidosis: Current Concepts, Challenges and Perspectives. Journal of Fungi 6:4, pages 267.
Crossref
Crossref
Mohamed Hassanein, Alaaeldeen Bashier, Hoosen Randeree, Megahed Abouelmagd, Waleed AlBaker, Bachar Afandi, Omar Abu Hijleh, Inass Shaltout, Magdy EI-Sharkawy, Selcuk Dagdelen & Samir Assaad Khalil. (2020) Use of SGLT2 inhibitors during Ramadan: An expert panel statement. Diabetes Research and Clinical Practice 169, pages 108465.
Crossref
Crossref
Jaspreet Kalra, Suresh Babu Mangali, Deepika Dasari, Audesh Bhat, Srashti Goyal, Indu Dhar, Dharamrajan Sriram & Arti Dhar. (2019) SGLT1 inhibition boon or bane for diabetes‐associated cardiomyopathy. Fundamental & Clinical Pharmacology 34:2, pages 173-188.
Crossref
Crossref
Salvatore Carbone & Dave L. Dixon. (2019) The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovascular Diabetology 18:1.
Crossref
Crossref
Maria Mirabelli, Eusebio Chiefari, Patrizia Caroleo, Raffaella Vero, Francesco Saverio Brunetti, Domenica Maria Corigliano, Biagio Arcidiacono, Daniela Patrizia Foti, Luigi Puccio & Antonio Brunetti. (2019) Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus. Journal of Diabetes Research 2019, pages 1-8.
Crossref
Crossref
Anastasios Tentolouris, Panayotis Vlachakis, Evangelia Tzeravini, Ioanna Eleftheriadou & Nikolaos Tentolouris. (2019) SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. International Journal of Environmental Research and Public Health 16:16, pages 2965.
Crossref
Crossref
Vishal Gupta, Michael Willis, Pierre Johansen, Andreas Nilsson, Manan Shah, Amey Mane & Cheryl Neslusan. (2019) Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. Value in Health Regional Issues 18, pages 65-73.
Crossref
Crossref
Joakim Huber, Michael Smeikal, Christoph H. Saely, Harald Stingl, Monika Lechleitner & Peter Fasching. (2019) Geriatrische Aspekte bei Diabetes mellitus (Update 2019)Geriatric aspects for the management of diabetes mellitus (Update 2019). Wiener klinische Wochenschrift 131:S1, pages 236-245.
Crossref
Crossref
Kasper S Madsen, Pernille Kähler, Lise Katrine Aronsen Kähler, Sten Madsbad, Filip Gnesin, Maria-Inti Metzendorf, Bernd Richter & Bianca Hemmingsen. (2019) Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Hiroki Yokoyama, Ami Nagao, Sanae Watanabe & Jun Honjo. (2018) Incidence and risk of vaginal candidiasis associated with sodium–glucose cotransporter 2 inhibitors in real‐world practice for women with type 2 diabetes. Journal of Diabetes Investigation 10:2, pages 439-445.
Crossref
Crossref
Maswood M. Ahmad, Imad Addin Brema & Mussa H. Almalki. 2019. Type 2 Diabetes [Working Title]. Type 2 Diabetes [Working Title].
Pankaj Aneja, Gaurav Bhalla, Neeti Parvesh, Kunal Aneja & Kashish Aneja. (2019) Efficacy and safety of canagliflozin 300 mg in overweight and obese type 2 diabetes mellitus patients in a real-world setting: COLOR study. Indian Journal of Endocrinology and Metabolism 23:3, pages 307.
Crossref
Crossref
Riobaldo Cintra, Filipe A Moura, Luis Sergio F de Carvalho, Joaquim Barreto, Marcos Tambascia, Roberto Pecoits-Filho & Andrei C. Sposito. (2019) Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. Revista da Associação Médica Brasileira 65:1, pages 70-86.
Crossref
Crossref
Sruthi Adimadhyam, Glen T. Schumock, Gregory S. Calip, Daphne E. Smith Marsh, Brian T. Layden & Todd A. Lee. (2018) Increased risk of mycotic infections associated with sodium–glucose co‐transporter 2 inhibitors: a prescription sequence symmetry analysis. British Journal of Clinical Pharmacology 85:1, pages 160-168.
Crossref
Crossref
Antonio Toniolo, Gianluca Cassani, Anna Puggioni, Agostino Rossi, Alberto Colombo, Takashi Onodera & Ele Ferrannini. (2019) The diabetes pandemic and associated infections: suggestions for clinical microbiology. Reviews in Medical Microbiology 30:1, pages 1-17.
Crossref
Crossref
Laura Patakfalvi, Anne-Sophie Brazeau & Kaberi Dasgupta. (2018) Physician experiences with sodium-glucose cotransporter (SGLT2) inhibitors, a new class of medications in type 2 diabetes, and adverse effects. Primary Health Care Research & Development 20.
Crossref
Crossref
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding & Marc S Sabatine. (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet 393:10166, pages 31-39.
Crossref
Crossref
David W Denning, Matthew Kneale, Jack D Sobel & Riina Rautemaa-Richardson. (2018) Global burden of recurrent vulvovaginal candidiasis: a systematic review. The Lancet Infectious Diseases 18:11, pages e339-e347.
Crossref
Crossref
D. A. Lebedev & A. Yu. Babenko. (2018) Use of sodium-glucose co-transporter-2 inhibitors from clinical trial results to practical application in Russia. Medical Council:16, pages 100-108.
Crossref
Crossref
Amerta Ghosh, Ritesh Gupta, Padam Singh, Abhinav Dutta & Anoop Misra. (2018) Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes in North India: A 12-month prospective study in real-world setting. International Journal of Clinical Practice 72:9, pages e13237.
Crossref
Crossref
Ronnie Aronson, Juan Frias, Allison Goldman, Amanda Darekar, Brett Lauring & Steven G. Terra. (2018) Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes, Obesity and Metabolism 20:6, pages 1453-1460.
Crossref
Crossref
Cheryl Neslusan, Anna Teschemaker, Michael Willis, Pierre Johansen & Lien Vo. (2018) Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. Diabetes Therapy 9:2, pages 565-581.
Crossref
Crossref
Ken Yan Thong, Mahender Yadagiri, Dennis Joseph Barnes, David Stuart Morris, Tahseen Ahmad Chowdhury, Ling Ling Chuah, Anthony Michael Robinson, Stephen Charles Bain, Karen Ann Adamson & Robert Elford John Ryder. (2018) Clinical risk factors predicting genital fungal infections with sodium–glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit. Primary Care Diabetes 12:1, pages 45-50.
Crossref
Crossref
Xin‐Lin Zhang, Qing‐Qing Zhu, Yu‐Han Chen, Xue‐Ling Li, Fu Chen, Jian‐An Huang & Biao Xu. (2018) Cardiovascular Safety, Long‐Term Noncardiovascular Safety, and Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta‐Analysis With Trial Sequential Analysis. Journal of the American Heart Association 7:2.
Crossref
Crossref
Lucia M. Novak & Davida F. Kruger. (2017) Bolstering your armamentarium with SGLT2 inhibitors. The Nurse Practitioner 42:10, pages 28-34.
Crossref
Crossref
Emma D. Deeks & André J. Scheen. (2017) Canagliflozin: A Review in Type 2 Diabetes. Drugs 77:14, pages 1577-1592.
Crossref
Crossref
Ashley M. Zurek, Raghunandan Yendapally & Elizabeth M. Urteaga. (2017) A Review of the Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis. Diabetes Spectrum 30:2, pages 137-142.
Crossref
Crossref
Paresh Dandona & Ajay Chaudhuri. (2017) Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician. International Journal of Clinical Practice 71:5, pages e12937.
Crossref
Crossref
Oluwaranti F. Akiyode & Adebola A. Adesoye. (2016) Adverse Effects Associated With Newer Diabetes Therapies. Journal of Pharmacy Practice 30:2, pages 238-244.
Crossref
Crossref
Norberto Perico, Piero Ruggenenti & Giuseppe Remuzzi. (2017) ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. Current Opinion in Pharmacology 33, pages 34-40.
Crossref
Crossref
George Grunberger. (2017) Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?. Current Diabetes Reports 17:4.
Crossref
Crossref
Hermann Koepsell. (2017) The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacology & Therapeutics 170, pages 148-165.
Crossref
Crossref
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt & Norman Waugh. (2017) Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technology Assessment 21:2, pages 1-218.
Crossref
Crossref
Abd A. Tahrani, Anthony H. Barnett & Clifford J. Bailey. (2016) Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nature Reviews Endocrinology 12:10, pages 566-592.
Crossref
Crossref
André J. Scheen. (2016) SGLT2 Inhibitors: Benefit/Risk Balance. Current Diabetes Reports 16:10.
Crossref
Crossref
H. W. Rodbard, J. Seufert, N. Aggarwal, A. Cao, A. Fung, M. Pfeifer & M. Alba. (2016) Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes, Obesity and Metabolism 18:8, pages 812-819.
Crossref
Crossref
Danny Meetoo, Louise Wong & Sabah Alsomali. (2016) Pharmacological options for managing type 2 diabetes. Nurse Prescribing 14:7, pages 330-338.
Crossref
Crossref
Pamela Kushner. (2016) Benefits/Risks of Sodium–Glucose Co-Transporter 2 Inhibitor Canagliflozin in Women for the Treatment of Type 2 Diabetes. Women's Health 12:3, pages 379-388.
Crossref
Crossref
Richard E. Gilbert, Matthew R. Weir, Paola Fioretto, Gordon Law, Mehul Desai, Irina Kline, Wayne Shaw & Gary Meininger. (2016) Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. Canadian Journal of Diabetes 40:3, pages 247-257.
Crossref
Crossref
Joakim Huber, Michael Smeikal, Monika Lechleitner & Peter Fasching. (2016) Geriatrische Aspekte bei Diabetes mellitusGeriatric aspects for the management of diabetes mellitus. Wiener klinische Wochenschrift 128:S2, pages 124-130.
Crossref
Crossref
Gary C.W. Chan & Sydney C.W. Tang. (2016) Diabetic nephropathy: landmark clinical trials and tribulations. Nephrology Dialysis Transplantation 31:3, pages 359-368.
Crossref
Crossref
Zachary T. Bloomgarden & Yehuda Handelsman. (2015) Sglt-2 Inhibition Added to Glp-1 Agonist Therapy for Type 2 Diabetes: What is the Benefit?. Endocrine Practice 21:12, pages 1442-1444.
Crossref
Crossref
L. Merker, H-U. Häring, A. V. Christiansen, F. Roux, A. Salsali, G. Kim, T. Meinicke, H. J. Woerle & U. C. Broedl. (2015) Empagliflozin as add-on to metformin in people with Type 2 diabetes. Diabetic Medicine 32:12, pages 1555-1567.
Crossref
Crossref
Cheryl Neslusan, Anna Teschemaker, Pierre Johansen, Michael Willis, Atanacio Valencia-Mendoza & Andrea Puig. (2015) Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. Value in Health Regional Issues 8, pages 8-19.
Crossref
Crossref
Stephan Matthaei, Doina Catrinoiu, Aleksander Celiński, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Nayyar Iqbal & Lars Hansen. (2015) Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes. Diabetes Care 38:11, pages 2018-2024.
Crossref
Crossref
Norm Rosenthal, Gary Meininger, Kirk Ways, David Polidori, Mehul Desai, Rong Qiu, Maria Alba, Frank Vercruysse, Dainius Balis, Wayne Shaw, Robert Edwards, Scott Bull, Nicholas Di Prospero, Sue Sha, Paul Rothenberg, William Canovatchel & Keith Demarest. (2015) Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Annals of the New York Academy of Sciences 1358:1, pages 28-43.
Crossref
Crossref
S. Matthaei, K. Bowering, K. Rohwedder, J. Sugg, S. Parikh & E. Johnsson. (2015) Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. Diabetes, Obesity and Metabolism 17:11, pages 1075-1084.
Crossref
Crossref
Ting Yang, Min Lu, Lingyue Ma, Ying Zhou & Yimin Cui. (2015) Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis. European Journal of Clinical Pharmacology 71:11, pages 1325-1332.
Crossref
Crossref
S. A. Brunton. (2015) The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. International Journal of Clinical Practice 69:10, pages 1071-1087.
Crossref
Crossref
Greg Fulcher, David R. Matthews, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Robert Weiss, Julio Rosenstock, George Capuano, Mehul Desai, Wayne Shaw, Frank Vercruysse, Gary Meininger & Bruce Neal. (2015) Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Therapy 6:3, pages 289-302.
Crossref
Crossref
George Dailey. (2015)
Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on
P
hase 3 trials 艾格列净治疗2型糖尿病：基于3期试验的安全性与有效性概述
. Journal of Diabetes 7:4, pages 448-461.
Crossref
Crossref
S. Del Prato, M. Nauck, S. Durán‐Garcia, L. Maffei, K. Rohwedder, A. Theuerkauf & S. Parikh. (2015) Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data. Diabetes, Obesity and Metabolism 17:6, pages 581-590.
Crossref
Crossref
Gary Meininger, William Canovatchel, David Polidori & Norm Rosenthal. (2015) Canagliflozin for the treatment of adults with Type 2 diabetes. Diabetes Management 5:3, pages 183-201.
Crossref
Crossref
Deborah Hinnen. (2015) Short commentary on empagliflozin and its potential clinical impact. Therapeutic Advances in Endocrinology and Metabolism 6:2, pages 68-81.
Crossref
Crossref
John P.H. Wilding, Lawrence Blonde, Lawrence A. Leiter, Sonia Cerdas, Cindy Tong, Jacqueline Yee & Gary Meininger. (2015) Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. Journal of Diabetes and its Complications 29:3, pages 438-444.
Crossref
Crossref
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba, Joel Jiang, Frank Vercruysse, Gary Meininger & David Matthews. (2015) Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. Diabetes Care 38:3, pages 403-411.
Crossref
Crossref
B. Bode, K. Stenlöf, S. Harris, D. Sullivan, A. Fung, K. Usiskin & G. Meininger. (2015) Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes, Obesity and Metabolism 17:3, pages 294-303.
Crossref
Crossref
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L. Peters, Apostolos Tsapas, Richard Wender & David R. Matthews. (2015) Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58:3, pages 429-442.
Crossref
Crossref
Curtis TriplittSusan Cornell. (2015) Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus. Clinical Medicine Insights: Endocrinology and Diabetes 8, pages CMED.S31526.
Crossref
Crossref
Virginia Valentine & Deborah Hinnen. (2015) Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes. Clinical Diabetes 33:1, pages 5-13.
Crossref
Crossref
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L. Peters, Apostolos Tsapas, Richard Wender & David R. Matthews. (2015) Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:1, pages 140-149.
Crossref
Crossref
B. Guerci. (2015) Les inhibiteurs de SGLT2 : pour quels patients ? Quelle place dans la stratégie thérapeutique ?. Médecine des Maladies Métaboliques 9:1, pages S49-S58.
Crossref
Crossref
André J. Scheen. (2014) Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Drugs 75:1, pages 33-59.
Crossref
Crossref
S. Halimi & B. Vergès. (2014) Adverse effects and safety of SGLT-2 inhibitors. Diabetes & Metabolism 40:6, pages S28-S34.
Crossref
Crossref
J.-F. Yale, G. Bakris, B. Cariou, J. Nieto, E. David-Neto, D. Yue, E. Wajs, K. Figueroa, J. Jiang, G. Law, K. Usiskin & G. Meininger. (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes, Obesity and Metabolism 16:10, pages 1016-1027.
Crossref
Crossref
John P.H. Wilding. (2014) The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 63:10, pages 1228-1237.
Crossref
Crossref
Sue Sha, Damayanthi Devineni, Atalanta Ghosh, David Polidori, Marcus Hompesch, Sabine Arnolds, Linda Morrow, Heike Spitzer, Keith Demarest & Paul Rothenberg. (2014) Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes. PLoS ONE 9:8, pages e105638.
Crossref
Crossref
Chang Hee JungJung Eun JangJoong-Yeol Park. (2014) A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor. Diabetes & Metabolism Journal 38:4, pages 261.
Crossref
Crossref